{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
m deucravacitinib
to a specific field?
Status:
US Approved Rx
(2024)
Source:
NDA218614
(2024)
Source URL:
First approved in 2024
Source:
NDA218614
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT02580552: Phase 1 Interventional Completed Cutaneous T-cell Lymphoma (CTCL)
(2016)
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
INN:zilebesiran [INN]
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Class:
NUCLEIC ACID